Buy Eskalith

Eskalith

Eskalith: What Is It?

Eskalith is a brand-name medication that contains lithium carbonate as its active ingredient. Lithium carbonate belongs to the class of mood-stabilising agents used in mental health care. It is available in the United Kingdom as a 300 mg pill and is prescribed only with a doctor’s authorization (prescription-only medicine).

The Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval and safety monitoring of Eskalith in the UK.

How Eskalith Works in the Body

Lithium’s exact mechanism is not fully understood, but several actions have been identified:

• It influences second-messenger systems (e.g., inositol monophosphatase inhibition) that modify neuronal signaling.
• Lithium modulates the activity of neurotransmitters such as serotonin and dopamine, helping to stabilize mood swings.
• It affects gene expression and neuroprotective pathways, which may contribute to long-term mood regulation.

These biochemical effects collectively reduce the frequency and severity of manic and depressive episodes in people with bipolar disorder.

Conditions Treated with Eskalith

Eskalith is MHRA-approved for the following indications:

• Maintenance treatment of bipolar disorder - preventing recurrence of manic or depressive episodes.
• Acute treatment of mania associated with bipolar disorder (often in combination with antipsychotics).

These uses are based on extensive clinical research and are reflected in the product’s prescribing information.

Off-Label and Investigational Applications

Evidence from peer-reviewed studies supports some off-label uses, although they are not approved by the MHRA:

• Augmentation in treatment-resistant major depressive disorder - lithium has been shown in randomized trials to improve response when added to antidepressants. Off-label use requires close medical supervision and regular blood-level monitoring.

• Prevention of suicidal behaviour - meta-analyses suggest lithium reduces suicide risk in patients with mood disorders. This indication remains off-label and must be weighed against potential toxicity.

Who Should (Not) Use Eskalith?

Ideal Candidates

• Adults diagnosed with bipolar disorder who need long-term mood stabilization.
• Individuals whose serum lithium levels can be reliably monitored.

Absolute Contra-indications

• Known hypersensitivity to lithium or any component of the pill.
• Severe renal impairment (eGFR < 30 mL/min/1.73 m²) or end-stage renal disease.
• Pregnancy-associated hyperthyroidism or untreated thyroid disease (lithium can exacerbate thyroid dysfunction).
• Use in breast-feeding mothers without specialist advice (lithium passes into breast milk).

Relative Contra-indications

• Mild-to-moderate renal impairment (dose adjustment and close monitoring required).
• Thyroid disorders - lithium may cause hypothyroidism; thyroid function should be checked regularly.
• Cardiovascular disease - lithium can affect heart rhythm; ECG monitoring may be advised.
• Elderly patients - increased sensitivity to side effects; start with lower doses.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Tremor (usually fine-handed) - often managed by dose adjustment.
• Increased thirst and urination - maintain adequate fluid intake while avoiding excess.
• Weight gain - monitor diet and physical activity.
• Mild gastrointestinal upset - take the pill with food if needed.

Serious Adverse Events

• Lithium toxicity - symptoms include severe nausea, vomiting, confusion, seizures, and cardiac arrhythmia. Immediate medical attention is required.
• Renal toxicity - long-term use can reduce kidney function; regular renal tests are essential.
• Thyroid dysfunction - hypothyroidism may develop; periodic thyroid-stimulating hormone (TSH) checks are recommended.
• Neurological effects - at high levels, lithium can cause ataxia, slurred speech, and muscle weakness.

Drug Interactions

• Diuretics (thiazides, loop diuretics) - increase lithium levels; dose reduction or close monitoring is needed.
• Non-steroidal anti-inflammatory drugs (NSAIDs) - may raise lithium concentrations.
• ACE inhibitors and ARBs - elevate lithium levels; monitor serum lithium.
• Selective serotonin reuptake inhibitors (SSRIs) - can modestly increase lithium levels; watch for serotonin-related side effects.
• Caffeine and high-sodium diets - lower sodium can raise lithium levels; maintain consistent dietary sodium.

Food and Lifestyle Interactions

• Consistent sodium intake - sudden changes in salt consumption affect lithium clearance.
• Alcohol - may worsen dehydration and increase toxicity risk; limit intake.
• Driving or operating machinery - lithium rarely impairs cognition, but if dizziness or tremor occurs, exercise caution.

How to Take Eskalith

• Standard dosing: The usual starting dose is 300 mg once daily, taken with a full glass of water. Doses are adjusted based on serum lithium levels, typically aiming for 0.6-1.2 mmol/L.
• Titration: Dose increases are made in 300 mg increments, usually after 5-7 days, once a stable serum level is confirmed.
• Special populations:
• Renal impairment - start at 150 mg daily and titrate slowly.
• Elderly - consider a lower initial dose (150 mg) and monitor closely.
• Administration: Swallow the pill whole; do not crush or chew.
• Missed dose: Take the missed dose as soon as remembered unless it is close to the next scheduled dose. Do not double a dose.
• Overdose: Symptoms include severe vomiting, diarrhea, tremor, and confusion. Seek emergency care; dialysis may be required in severe cases.
• Discontinuation: Abrupt stopping can precipitate rebound mania or depression. Taper gradually under medical supervision, usually decreasing by 300 mg every 1-2 weeks.

Monitoring and Follow-Up

• Serum lithium level: Check 5-7 days after dose changes and at least every 3 months once stable.
• Renal function: Measure serum creatinine and eGFR every 6 months (more frequently if risk factors exist).
• Thyroid function: Obtain TSH and free T4 at baseline, then annually.
• Electrolytes: Sodium and calcium levels should be monitored when diuretics or other interacting drugs are used.
• Clinical assessment: Patients should report new tremor, extreme thirst, or changes in mood promptly.

Storage and Handling

• Store Eskalith tablets at room temperature (15-30 °C), away from moisture and direct sunlight.
• Keep the container tightly closed and out of reach of children.
• Do not use the medication after the expiry date printed on the package.
• Dispose of unused tablets according to local pharmacy take-back programs or the instructions on the label.

Medication-Specific Glossary

Therapeutic Window

The serum lithium concentration range (0.6-1.2 mmol/L) where the drug is effective without causing toxicity.

Serum Lithium Level

The amount of lithium measured in the blood, used to guide dosing and safety monitoring.

Renal Clearance

The process by which the kidneys eliminate lithium; impaired clearance raises the risk of toxicity.

Medical Disclaimer

This article provides educational information about Eskalith and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.